Schweppe K-W
Frauenklinik, Ammerland Klinik GmbH, Akademisches Lehrkrankenhaus der Universität Göttingen.
Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):276-80. doi: 10.1055/s-2003-42282.
Progestins are used for the treatment of endometriosis and endometriosis related complains in low dosages since more than four decades. Progestins induce incomplete regression of endometriotic implants only, they have a high recurrence rate, and they cause side effects--depending of the type of progestin and doses used--therefore GnRH-Agonist induced reversible ovarian suppression has become the standard in medical therapy for endometriosis prior and after surgery during the last ten years. New follow up studies have demonstrated the this new therapeutic principle is associated with relevant recurrence rates also and we have learned, that endometriosis is a chronic disease. For this background a medical therapy, which has low subjective and objective side effects, which can be used repeatedly or over a long time period, and which is cost effective becomes more important. This means that the place of progestins in the treatment of endometriosis has to be defined again and prospective randomised studies with the different substances are necessary.
四十多年来，低剂量孕激素一直用于治疗子宫内膜异位症及与子宫内膜异位症相关的症状。孕激素仅能使异位内膜不完全消退，复发率高，且会引起副作用（取决于所用孕激素的类型和剂量），因此，在过去十年中，促性腺激素释放激素激动剂诱导的可逆性卵巢抑制已成为子宫内膜异位症手术前后药物治疗的标准方法。新的随访研究表明，这种新的治疗原则也伴有较高的复发率，而且我们了解到，子宫内膜异位症是一种慢性疾病。基于这一背景，一种主观和客观副作用小、可反复或长期使用且具有成本效益的药物治疗变得更为重要。这意味着必须重新界定孕激素在子宫内膜异位症治疗中的地位，有必要对不同药物进行前瞻性随机研究。
